Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche : Secures EU Nod For Tecentriq in Metastatic Non-Small Cell Lung Cancer Patients

05/05/2021 | 01:49am EDT


ę MT Newswires 2021
All news about ROCHE HOLDING AG
06/11AbbVie Sees Continued Positive Results for Leukemia Treatment
DJ
06/11ROCHEá : Blood Cancer Combo Shows Efficacy in Three Late Stage Studies
MT
06/11ROCHEá : Evrysdi Shows Improvement In Pre-Symptomatic Infants With Spinal Muscul..
MT
06/11GENENTECHá : Announces Data at EHA2021 Reinforcing Efficacy of Venclexta Combina..
BU
06/11ROCHEá : announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto c..
AQ
06/11PRESS RELEASE : Roche announces data at EHA2021 -2-
DJ
06/11PRESS RELEASEá : Roche announces data at EHA2021 reinforcing efficacy of Venclex..
DJ
06/11ROCHEá : New Roche data for Evrysdi show improved motor function in pre-symptoma..
AQ
06/11ROCHEá : New Genentech Data for Evrysdi (risdiplam) Show Improved Motor Function..
BU
06/11PRESS RELEASE : New Roche data for Evrysdi show -2-
DJ
More news
Financials
Sales 2021 60 596 M 67 449 M 67 449 M
Net income 2021 14 651 M 16 309 M 16 309 M
Net cash 2021 5 021 M 5 589 M 5 589 M
P/E ratio 2021 19,9x
Yield 2021 2,74%
Capitalization 295 B 329 B 329 B
EV / Sales 2021 4,79x
EV / Sales 2022 4,64x
Nbr of Employees 101 465
Free-Float 83,4%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 353,70 CHF
Last Close Price 342,00 CHF
Spread / Highest target 28,1%
Spread / Average Target 3,42%
Spread / Lowest Target -15,2%
EPS Revisions
Managers and Directors
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG10.68%328 612
JOHNSON & JOHNSON4.82%434 405
PFIZER, INC.9.07%224 747
NOVARTIS AG-0.39%208 035
ABBVIE INC.7.72%203 857
ELI LILLY AND COMPANY32.72%203 704